In this "Summer Edition" we are pleased to announce the FDA 510 (k) clearance of the BÜHLMANN fCAL® ELISA. We make mention of upcoming meetings where you can find us such as American Association of Clinical Chemistry (AACC) and the Association of Medical Laboratory Immunologists (AMLI) annual meetings. Additionally, we share the exciting happenings pertaining to IBDoc® Calprotectin Home test that have placed BUHLMANN in the news. (US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3)
WHAT'S NEW
BÜHLMANN Laboratories AG, is proud to announce that it has received United States Food and Drug Administration (FDA) 510(k) clearance of its BÜHLMANN fCAL® ELISA.
The BÜHLMANN fCAL® ELISA is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohns disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.
Upcoming Meeting: AACC 2018:
Come by Booth 4563 to learn about our Calprotectin, TDM, Chemistry, Neuroimmunology, and Cellular Allergy Portfolios.
Upcoming Meeting: AMLI 2018
Connect with our team at Booth #5 and learn about our Anti-MAG Autoantibodies ELISA and other assays in our Neuroimmunology and Autoimmunity product lines.
RESOURCES and RESEARCH
IBDoc® is now Part of the TactioRM
Tactio Health Group and Telia Company team up to accelerate the development of patient-centred digital health programs in Sweden and other Nordic and Baltic countries.
The Swedish telecommunication company Telia, together with AbbVie Sweden, developed the IBD Home platform using the TactioRPM platform. IBD Home is a complete IBD remote monitoring ecosystem. The IBD Home app allows patients to fill in symptom scores and other important information on their smartphone
Calprotectin Testing Goes Mobile
With the advances in technology and specifically the ubiquitous use of mobile devices developed during the last decade, a huge opportunity has arisen to change the way some healthcare services are provided.
|
|
First IBD Nurse led IBDoc Study
Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video.
|
|
IBDoc SwissMedtech Award Nominee
At this years SwissMedtech Day, BÜHLMANN was nominated to receive the Swiss Medtech Award. Switzerland is listed by key rankings as the globally most innovative country. Medtech one of the industries heavily contributing to this ranking. Out of 25 applications BÜHLMANN Laboratories AG was chosen to present IBDoc® to a Jury of Medtech and academic representatives.
BÜHLMANN HIGHLIGHTS
BÜHLMANN fCAL® ELISA has rock-solid performance that provides you with optimal precision to measure your results. Focus on what really matters calprotectin results you can stand behind. Increase your efficiency and cost savings with the most sensitive fCAL assay the FDA has registered.
BUHLMANN DIAGNOSTICS CORP
BÜHLMANN is unique, independent, and reliable in every aspect of its business from the outstanding quality of its products, its excellent after-sales services, and its remarkable scientific innovations. The establishment of BDC is a statement of the importance of you, our customers and our commitment to understanding your needs. Our North American affiliate will help us to continue to foster closer relationships with our customers and enhance our customer support interactions as well as meet your requirements for future BÜHLMANN products. Quality is not just a statement, but part of our daily mission.
105 Route 101A, Suite 1,
Amherst, NH 03031 USA
Ph: (844) 300-9799
info@buhlmannlabs.com
www.buhlmannlabs.com
|
|
|
|